Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Colorcon
Harvard Business School
McKinsey
McKesson

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,723,390

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,723,390 protect, and when does it expire?

Patent 7,723,390 protects TIROSINT and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 7,723,390
Title:Pharmaceutical formulations for thyroid hormones
Abstract:The present invention provides for pharmaceutical formulations based on thyroid hormones enabling a safe and stable oral administration in the framework of the strict therapeutic index prescribed in case of thyroid disorders.
Inventor(s): Garavani; Alberto (Ponte Capriasca, CH), Marchiorri; Maurizio (Valbrona, IT), Di Martino; Alessandro (Milan, IT), Mateo Echanagorria; Angel (Milan, IT)
Assignee: Altergon S.A. (Lugano, CH)
Application Number:10/188,467
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,723,390
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Recent additions to Drugs Protected by US Patent 7,723,390

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE 021924 Aug 1, 2007 RX Yes   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE 021924 Oct 13, 2006 RX Yes   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE 021924 Oct 2, 2009 RX Yes   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE 021924 Apr 25, 2017 RX Yes   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 7,723,390

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-013 Aug 1, 2007 RX Yes No   Start Trial   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-002 Oct 13, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-003 Oct 13, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-004 Oct 13, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-010 Oct 2, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-005 Oct 13, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-008 Oct 2, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,723,390

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2001A1401Jul 02, 2001

International Family Members for US Patent 7,723,390

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 312621   Start Trial
Canada 2392545   Start Trial
Germany 60207951   Start Trial
Denmark 1291021   Start Trial
European Patent Office 1291021   Start Trial
Spain 2254559   Start Trial
Italy MI20011401   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Boehringer Ingelheim
Colorcon
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.